Cellular Mechanisms for Dopamine D4 Receptor-induced Homeostatic Regulation of α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid (AMPA) Receptors*S

Received for publication, January 13, 2011, and in revised form, May 25, 2011 Published, JBC Papers in Press, May 27, 2011 DOI 10.1074/jbc.M111.221416

Eunice Y. Yuen and Zhen Yan†

From the Department of Physiology and Biophysics, School of Medicine and Biomedical Sciences, The State University of New York at Buffalo, Buffalo, New York 14214

Aberrant dopamine D4 receptor function has been implicated in mental illnesses, including schizophrenia and attention deficit-hyperactivity disorder. Recently, we have found that D4 receptor exerts an activity-dependent bi-directional regulation of AMPA receptor (AMPA)–mediated synaptic currents in pyramidal neurons of prefrontal cortex (PFC) via the dual control of calcium/calmodulin kinase II (CaMKII) activity. In this study, we examined the signaling mechanisms downstream of CaMKII that govern the complex effects of D4 on glutamatergic transmission. We found that in PFC neurons at high activity state, D4 suppresses AMPAR responses by disrupting the kinesin motor–based transport of GluR2 along microtubules, which was accompanied by the D4 reduction of microtubule stability via a mechanism dependent on CaMKII inhibition. On the other hand, in PFC neurons at the low activity state, D4 potentiates AMPAR responses by facilitating synaptic targeting of GluR1 through the scaffold protein SAP97 via a mechanism dependent on CaMKII stimulation. Taken together, these results have identified distinct signaling mechanisms underlying the homeostatic regulation of glutamatergic transmission by D4 receptors, which may be important for cognitive and emotional processes in which dopamine is involved.

The mesocortical dopamine inputs from ventral tegmental area to prefrontal cortex (PFC) is involved in many cognitive functions, such as motivation (1), reinforcement learning (2), and working memory (3, 4). Dopamine exerts its action via D1-like (D1, D3) and D2-like (D2, D3, D4) receptors (4, 5). D4 receptor (D4R) is preferentially distributed in PFC (6, 7), suggesting its prominent role in this brain area.

D4 receptor is of particular interest because of its potent affinity to atypical antipsychotics, such as clozapine, which has fewer extrapyramidal side effects compared with typical antipsychotics with D2 antagonism (8, 9). The D4R gene polymorphisms with variable tandem repeats have been implicated in the prevalence of several mental disorders, including attention deficit-hyperactivity disorder (ADHD) (10, 11), Tourette syndrome (12), and substance abuse (13, 14). Moreover, human studies suggest that the gene polymorphisms correlate with the PFC gray matter volume (15) and responsiveness to medication in ADHD patients (16). In animal studies, mice lacking D4R show cortical hyperexcitability (17), decreased novelty exploration (18), and increased locomotor sensitivity to psychostimulants (19). These findings support the essential role of D4R in normal PFC functioning as well as in many neuropsychiatric disorders.

Growing evidence suggests a homeostatic function of D4 receptors in PFC. Behavioral studies show that a D4 antagonist may enhance or suppress working memory depending on the base line performance (20). Our previous studies have identified two homeostatic targets of D4: CaMKII and AMPAR (21, 22). At high neuronal activity, D4 suppresses AMPAR–mediated synaptic transmission by decreasing CaMKII activity. Conversely, at low neuronal activity, D4 potentiates AMPAR trafficking and function by increasing CaMKII enzymatic activity and synaptic redistribution (22, 23). Such a D4-mediated, state–dependent homeostatic mechanism could be highly relevant to the pathophysiology of ADHD and schizophrenia, in which weakened D4 function and dysregulation of glutamatergic transmission have been implicated. In this study, we have dissected out the mechanisms downstream of CaMKII that are responsible for the activity-dependent bi-directional regulation of AMPARs by D4 in PFC pyramidal neurons.

MATERIALS AND METHODS

Synaptic Current Recording in PFC Cultures—All experiments were carried out with the approval of the State University of New York at Buffalo Animal Care Committee. PFC cultures were prepared from 18-day rat embryos and maintained for 3–4 weeks in vitro. In some experiments, cultures were pretreated with the GABAAR antagonist bicuculline (10 μM, 2 h) or TTX (0.5 μM, 2 h) to elevate or dampen basal neuronal activity, respectively. AMPAR–mediated mEPSC was recorded as described previously (24). The internal solution contained 130 mM cesium methanesulfonate, 10 mM CsCl, 4 mM NaCl, 1 mM MgCl2, 10 mM HEPES, 5 mM EGTA, 2.2 mM lidocaine, 12 mM phosphocreatine, 5 mM MgATP, 0.5 mM Na2GTP, 0.1 mM leupeptin, pH 7.2–7.3, 265–270 mOsM. The external solution contained 127 mM NaCl, 5 mM KCl, 2 mM MgCl2, 2 mM CaCl2, 12

*This work was supported, in whole or in part, by National Institutes of Health Grant MH84233 (to Z. Y.).
†To whom correspondence should be addressed: Dept. of Physiology and Biophysics, State University of New York at Buffalo, 124 Sherman Hall, Buffalo, NY 14214. E-mail: zhanyen@buffalo.edu.
Mechanisms for D₄ Modulation of AMPARs

D₄ receptor agonist PD168077 maleate and the cytoskeleton disturbing agents phallolidin (Tocris), colchicines and paclitaxel (Taxol; Sigma) were made up as concentrated stocks in water or dimethyl sulfoxide and stored at −20 °C. Stocks were thawed and diluted immediately before use. The amino acid sequence for the dynamin inhibitory peptide is VQVPSRPNRAP. The peptide derived from the GluR2 C terminus that binds to GRIP is YGIESVKIA. The peptide obtained from the GluR1 C terminus that interacts with synapse-associated protein 97 (SAP97) is SSGMPLGATGL. Antibodies were dialyzed into neurons through the patch electrode to perturb the function of endogenous proteins, including anti-kinesin (clone IBII; Sigma) and anti-SAP97 antibodies (Santa Cruz Biotechnology). Electrophysiological recordings were performed at least 20 min upon antibody infusion. Dialysis with peptides or antibodies through the patch pipette to influence intracellular proteins is a well-established approach widely used in patch clamp recordings, which can be found in our previous publications (21, 24).

Electrophysiological Recording in PFC Slices—Pyramidal neurons located in layer V of PFC from Sprague-Dawley rats (3–4 weeks postnatal) were recorded. Slice preparation procedures were similar to what was described before (25, 26). In brief, animals were anesthetized by inhaling 2-bromo-2-bromodifluoromethane (2-bromo-2-Bromoethane, Sigma) and decapitated. Brains were quickly removed and sliced (300 μm) with a Leica VP1000S Vibrotome while bathed in a HEPES-buffered saline solution. Slices were then incubated for 1–5 h at room temperature (22–24 °C) in a NaHCO₃-buffered saline (EBSS) bubbled with 95% O₂, 5% CO₂. Slices were pretreated with bicuculline (10 μM) or TTX (0.5 μM; both 2 h), similar to that in culture recordings. These reagents were washed off for −0.5 h before recordings, and care was taken to finish recordings within ~1.5 h after treatments.

To measure AMPAR-mediated synaptic transmission, we performed the standard whole cell recording techniques in PFC slices (21, 26). Patch pipettes were filled with the same internal solution as that used in culture recordings. PFC slices were perfused with oxygenated artificial cerebrospinal fluid (130 mM NaCl, 26 mM NaHCO₃, 1 mM CaCl₂, 5 mM MgCl₂, 3 mM KCl, 10 mM glucose, 1.25 mM NaH₂PO₄). Neurons were observed with a ×40 water-immersion lens and illuminated with near infrared light, and the image was captured with an infrared-sensitive CCD camera. Recordings were performed using a Multiclamp 700A amplifier (Axon Instruments). Tight seals (2–10 gigaohms) were obtained by applying negative pressure. The membrane was disrupted with additional suction, and the whole cell configuration was obtained. Neurons were held at −70 mV, which is close to the measured EₓCl (−69.8 ± 0.1 mV, n = 10). Bipolar tungsten electrode (FHC, Inc.) was used to evoke EPSCs by stimulating the neighboring neurons (50-μs pulse).

AMPAR-EPSC was evoked every 10 s. Data analyses were performed with the Clampfit software (Axon Instruments).

Transfection, Viral Infection, Small Interference RNA (siRNA), and Antisense—Cultured PFC neurons (14–21 days in vitro) were transfected with D₄ siRNA (Santa Cruz Biotechnology), CaMKII siRNA (Ambion), dominant negative KIF5 (dnKIF5), or SAP97 siRNA (Santa Cruz Biotechnology) using the Lipofectamine 2000 method (24, 25). EGFP (Clontech) was co-transfected. Recording was performed in GFP-positive neurons 2–3 days after transfection. To overexpress active CaMKII, we infected PFC cultures (14 days in vitro) with truncated CaMKII Sindbis virus (tcCaMKII, 1–3 μl/ml medium, a gift from Dr. Julius Zhu at the University of Virginia). The biochemical experiment was performed 1 day after virus exposure. To knock down the expression of MAP2 in cultured PFC neurons, we used the antisense oligonucleotide 5′-TCGTCAGC-CATCCTTCAGATCTCT-3′ (27). The MAP2 sense oligonucleotide was used as a control. On DIV14, 1 μM of oligonucleotides were added directly to the culture medium. Two to 3 days after being exposed to these oligonucleotides, biochemical assays were performed on the cultured neurons.

Microtubule Stability Assay—Free tubulin was extracted as described previously (25). After pretreatment of bicuculline (10 μM, 2 h), virus infection or antisense application, cultured PFC neurons (14 days in vitro) in 3.5-cm dishes were washed twice with 1 ml of microtubule-stabilizing buffer (0.1 M MES, pH 6.75, 1 mM MgSO₄, 2 mM EGTA, 0.1 mM EDTA, and 4 mM glycerol). Cells were then incubated at 37 °C for 5 min in 600 μl of soluble tubulin extraction buffer (0.1 M MES, pH 6.75, 1 mM MgSO₄, 2 mM EGTA, 0.1 mM EDTA, 4 mM glycerol, and 0.1% Triton X-100) with the addition of protease inhibitor mixture tablets (Roche Diagnostics). The soluble extract was centrifuged at 37 °C for 2 min, and the supernatant was saved. An equal amount of protein was separated by 7.5% SDS-PAGE. Western blotting was performed using primary antibodies against α-tubulin and actin (both 1:2000; Sigma). Quantitative analysis was performed using ImageJ software.

Immunocytochemistry—After co-transfection of siRNA and EGFP, PFC cultures (21–24 days in vitro), were fixed (4% paraformaldehyde, 20 min), permeabilized (0.2% Triton X-100, 10 min), and blocked (5% BSA, 1 h). Neurons were next incubated with the antibody from antibody-D4R (sc-136169, 1:500; Santa Cruz Biotechnology), SAP97 (sc-9961, 1:500; Santa Cruz Biotechnology), MAP2 (sc-80012, 1:500; Santa Cruz Biotechnology), or PSD-95 (MA1–046, 1:500; Affinity Bioreagents) at 4 °C overnight. After three washes, they were incubated with the Alexa Fluor 594- (red) or Alexa Fluor 488- (green) conjugated secondary antibody (1:200, Molecular Probes) at room temperature for 1 h. Following three washes, the coverslips were mounted on slides with VECTASHIELD mounting media (Vector Laboratories). Fluorescent images were captured with a 40× or 100× objective and a cooled CCD camera mounted on a Nikon microscope using identical parameters.

RESULTS

D₄ Bi-directionally Regulates AMPAR Synaptic Response in an Activity-dependent Manner—To investigate whether D₄ regulates AMPARs in an activity-dependent manner, we...
recorded mEPSC, which represents the postsynaptic response to release of individual vesicles of glutamate, in cultured PFC pyramidal neurons pretreated with bicuculline (10 μM, 2 h) or TTX (0.5 μM, 2 h). Application of (2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo[f]quinoxaline-2,3-dione (NBQX, 10 μM) completely eliminated the mEPSC (n = 6), indicating that it is mediated by AMPARs. Co-staining with the neuronal marker MAP2 (Fig. 1A) indicated that D4R was present in almost all the cultured PFC neurons. Bath application of PD168077 (40 μM, 10 min) caused a small reduction of the mEPSC amplitude (as indicated by a leftward shift of the distribution) in untreated cultures (Fig. 1B, 16.8 ± 1.2%, n = 11, Fig. 1H), although this reducing effect of PD168077 was significantly augmented in bicuculline-pretreated cultures (Fig. 1C, 30.2 ± 1.3%, n = 10, Fig. 1H). The mEPSC frequency was also decreased to a larger extent by PD168077 in cultures pretreated with bicuculline (untreated: 11.1 ± 1.5%, n = 11; bicuculline-treated: 40.1 ± 8.9%, n = 10, Fig. 1H). However, in TTX-pretreated cultures, PD168077 significantly increased the mEPSC amplitude (Fig. 1D, 25.1 ± 4.7%, n = 12, Fig. 1H) and frequency (34.2 ± 5.8%, n = 12, Fig. 1H).

To test whether this bi-directional effect of PD168077 is mediated by D4 receptors, we transfected PFC cultures with a D4R siRNA. Specific knockdown of D4R was validated by immunocytochemistry (Fig. 1E). Cellular knockdown of D4R abolished the reducing effect of PD168077 on mEPSC in bicuculline-pretreated PFC cultures (amplitude: 2.8 ± 5.9%; frequency: 5.6 ± 2.5%; n = 8, Fig. 1H) and the enhancing effect of PD168077 on mEPSC in TTX-pretreated PFC cultures (amplitude: 1.5 ± 5.9%; frequency: 1.3 ± 2.6%; n = 7, Fig. 1H). Taken together, these results show that AMPAR-mediated synaptic response is suppressed by D4 at the high activity state and potentiated by D4 at the low activity state in cultured PFC neurons, consistent with the dual effects of D4 on evoked AMPAR-EPSC in PFC slices (21).

**Mechanisms for D4 Modulation of AMPARs**

**Dual Regulation of AMPARs by D4R Relies on CaMKII—**

Next, we examined the involvement of CaMKII in the dual effects of D4R in PFC cultures at different activity states. We first infected PFC cultures with the constitutively active CaMKII Sindbis virus (cCaMKII). As shown in Fig. 2A, in bicuculline-pretreated PFC cultures, the reducing effect of PD168077 on mEPSC was abolished in neurons infected with...
Mechanisms for D₄ Modulation of AMPARs

FIGURE 2. CaMKII is involved in the bi-directional regulation of AMPAR currents by D₄R in PFC cultures. A and C, cumulative plots of the distribution of mEPSC amplitude showing the effect of PD168077 in bicuculline (Bic, 10 μM, 2 h)-pretreated PFC cultures infected with tCaMKII versus GFP Sindbis virus (A) or in TTX (0.5 μM, 2 h)-pretreated cultures transfected with CaMKII siRNA versus a scrambled siRNA (C). Insets, representative mEPSC traces. Scale bars, 20 pA, 1 s.

To test the role of CaMKII further, we transfected cultured PFC neurons with a CaMKII siRNA. Our previous studies have shown that this CaMKII siRNA causes an effective knockdown of CaMKII expression (24). As shown in Fig. 2C, in TTX-pretreated PFC cultures, the enhancing effect of PD168077 on mEPSC was lost in CaMKII siRNA-transfected neurons (amplitude: 2.3 ± 3.1%; frequency: 8.3 ± 1.9%, n = 6, Fig. 2D), but not those transfected with a scrambled siRNA (amplitude: 27.5 ± 3.6%; frequency: 38.0 ± 7.2%, n = 6, Fig. 2D). Taken together, these results suggest that CaMKII plays a key role in the homeostatic regulation of AMPARs by D₄ receptors in cultured PFC neurons.

D₄ Depression of AMPARs at the High Activity State Is through a Mechanism Involving Microtubule/Kinesin Motor-based Transport of AMPARs—To examine the possible mechanism by which D₄ reduces AMPAR trafficking and function at the high activity state, we first tested the involvement of cytoskeletons. As shown in Fig. 3A, dialysis with paclitaxel (10 μM), a microtubule stabilizer, caused little change on AMPAR-EPSC by itself (7.8 ± 2.8%, n = 5) but blocked the reducing effect of PD168077 (4.1 ± 1.7%, n = 6, Fig. 3D). Bath application of the microtubule destabilizer colchicine (30 μM) reduced basal AMPAR-EPSC and occluded the effect of PD168077 (8.2 ± 2.0%, n = 7, Fig. 3D). However, the actin stabilizer phalloidin (10 μM) did not alter the effect of PD168077 (40.1 ± 2.4%, n = 4, Fig. 3D). Furthermore, dialysis with dynamin inhibitory peptide (100 μM) failed to block the effect of PD168077 (47.5 ± 1.5%, n = 8, Fig. 3D). These results suggest the involvement of microtubules, but not actin or clathrin/dynamin-dependent endocytosis, in the D₄ regulation of AMPARs.

Biochemical evidence shows that AMPAR and its binding protein GRIP are transported on microtubules by the kinesin motor protein KIF5 (28). To test further whether D₄ activation might suppress AMPAR synaptic delivery by interfering with the MT/KIF5/GRIP-mediated transport of AMPA receptors, we tested the role of GRIP in D₄ regulation of AMPAR-EPSC. A peptide derived from the C-terminal of GluR2 subunits (amino acids 871–883), which contains a functional sequence YGIES-VKIA that interferes with the endogenous GluR2-GRIP binding (29), was applied through the recording pipette. As shown in Fig. 3B, dialysis of the GluR2CT peptide (100 μM) reduced AMPAR-EPSC (51.7 ± 3.8%, n = 6) and occluded the effect of PD168077 (5.4 ± 1.6%, n = 5, Fig. 3D). A scrambled control peptide (100 μM) failed to change AMPAR-EPSC or the reducing effect of PD168077 (49.4 ± 2.1%, n = 5, Fig. 3D).

To examine the involvement of kinesin motors directly, we dialyzed a monoclonal antibody against KIF5, which is known to bind to kinesin and block the motor function (30), and examined the effect of PD168077 on AMPAR-EPSC in bicuculline-pretreated slices. As shown in Fig. 3C, dialyzing internal solution with anti-KIF5 (17 μg/ml) caused a gradual decline of AMPAR-EPSC (51.7 ± 6.3%, n = 6), consistent with the previous report (31), and markedly attenuated the reduction of AMPAR-EPSC by PD168077 (3.6 ± 1.6%, n = 8, Fig. 3D). Injection of the heat-inactivated anti-KIF5 failed to alter AMPAR-EPSC or the PD168077-mediated reduction of AMPAR-EPSC (43.8 ± 3.9%, n = 4, Fig. 3D). In contrast, dialysis with anti-KIF5 did not alter the enhancing effect of PD168077 on AMPAR-
To examine further the involvement of KIF5 motor proteins in the D₄ action, we transfected PFC cultures with a dominant negative KIF5 construct (generated by deleting the motor domain) and examined the effect of PD168077 on mEPSC in TTX-pretreated neurons. As shown in Fig. 3, E–G, in untransfected neurons (bicuculline-pretreated for 2 h), PD168077 caused a potent reduction of mEPSC amplitude (30.8 ± 3.6%, n = 13) and frequency (46.7 ± 6.9%, n = 13). Similar reduction was
Mechanisms for D₄ Modulation of AMPARs

In high activity PFC neurons, AMPAR mEPSC amplitude was significantly smaller (untransfected: 4.3 ± 1.4 pA, n = 14; transfected: 24.4 ± 1.8 pA, n = 14; p < 0.001, ANOVA) than in the absence of PD168077. *, p < 0.001, ANOVA.

PD168077 on microtubule depolymerization in PFC cultures (bicuculline-pretreated), the basal mEPSC amplitude was significantly smaller (untransfected: 41.6 ± 1.3 pA, n = 13; transfected: 24.4 ± 1.4 pA, n = 14; p < 0.001, ANOVA), whereas mEPSC frequency was largely unchanged (untransfected: 4.3 ± 0.5 Hz, n = 13; transfected: 4.6 ± 0.5 Hz, n = 14). Moreover, application of PD168077 had significantly diminished the effect on mEPSC amplitude (7.3 ± 1.7%, n = 14) and frequency (9.1 ± 2.0%, n = 14). It suggests that dominant negative KIF5 impairs the transport of functional AMPARs and occludes the reducing effect of D₄ receptors. Taken together, these data provide multiple lines of evidence demonstrating that D₄-induced depression of AMPAR-EPSC involves the KIF5-mediated transport of AMPAR-GRIK complex along microtubules on dendrites.

CaMKII Is Involved in D₄ Depression of Microtubule-based AMPAR Trafficking at the High Activity State—Because D₄-induced depression of glutamatergic transmission depends on the regulation of microtubule stability, we would like to know what molecules link D₄ receptors to the microtubule network. One possible mechanism to change microtubule dynamics is to change the phosphorylation state of MAP2, a dendrite-specific microtubule-associated protein (32), therefore altering the association of MAP2 with microtubules and microtubule stability (33, 34). CaMKII, which is primarily expressed in glutamatergic neurons, is known to phosphorylate MAP2 in the microtubule binding domain (35). Thus, we performed biochemical assays to test whether D₄ activation alters microtubule stability via a mechanism dependent on CaMKII and MAP2.

Western blot analysis was conducted in PFC cultures to detect the level of free tubulin (25), an indicator of microtubule depolymerization. As shown in Fig. 4A, application of PD168077 (40 μM, 10 min) caused a small increase in free tubulin (1.67 ± 0.14-fold of control, n = 3), and this increase was more prominent in bicuculline (10 μM, 2 h)-pretreated neurons (bicuculline: 1.86 ± 0.06-fold of control; bicuculline + PD: 4.46 ± 0.28-fold of control, n = 3), suggesting that the D₄ reduction of microtubule stability is activity-dependent.

To test the role of CaMKII in D₄ regulation of MT stability, we infected PFC cultures with constitutively active CaMKII Sindbis virus (tCaMKII). Cultures were treated with bicuculline for 2 h at 1 h after viral infection, followed by PD168077 application (40 μM, 10 min). As shown in Fig. 4B, D₄ activation significantly increased free tubulin in GFP-infected neurons (6.7 ± 1.3-fold of control, n = 5), but failed to do so in tCaMKII-infected cultures (1.2 ± 0.1-fold of control, n = 5). This suggests that D₄ reduces MT stability at the high activity state by a mechanism depending on CaMKII inhibition.

To test the involvement of MAP2, we treated PFC cultures (14 days in vitro) with MAP2 antisense oligonucleotides (27) to inhibit the expression of MAP2. As shown in Fig. 4B, MAP2 antisense treatment caused a significant elevation of the level of free tubulin and occluded the enhancing effect of D₄ (MAP2 antisense: 6.8 ± 0.33-fold of control; MAP2 antisense + PD: 7.3 ± 0.65 of control, n = 3), whereas MAP2 sense oligonucleotide was ineffective (MAP2 sense: 1.2 ± 0.42-fold of control; MAP2 sense + PD: 7.0 ± 0.7 of control, n = 3). This suggests that the D₄ reduction of MT stability at a high activity state is through a mechanism involving MAP2.

SAP97 Is Involved in the D₄/CaMKII Enhancement of AMPAR Synaptic Delivery and Synaptic Transmission at the Low Activity State—Next, we examined the potential mechanism involved in D₄/CaMKII-mediated increase of AMPAR trafficking and function in low activity PFC neurons. Previous studies have shown that SAP97, a member of membrane-associated guanylate kinase protein family, is selectively associated with GluR1 subunit (36, 37), and CaMKII-dependent phosphorylation of SAP97 at Ser²⁹ leads to increased targeting of SAP97 into dendritic spines (38). Thus, SAP97 provides a possible link between D₄-activated CaMKII and increased AMPAR surface delivery in PFC pyramidal neurons at the low activity state. To test this, we transfected PFC cultures with a SAP97 siRNA (GFP co-transfected). As shown in Fig. 5A, this SAP97 siRNA specifically knocked down the expression of SAP97 (in GFP⁻ neurons), but not the homolog protein PSD-95. After transfection, neurons were pretreated with TTX (0.5 μM, 2 h) before recording. As shown in Fig. 5, B and C, in neurons transfected with a scrambled siRNA, PD168077 significantly increased mEPSC (amplitude: 29.8 ± 3.2%, n = 8; frequency: 41.1 ± 7.2%, n = 9). Transfection of SAP97 siRNA caused a slight reduction of basal mEPSC amplitude (scrambled siRNA: 26.1 ± 1.7 pA, n = 9; SAP97 siRNA: 20.1 ± 1.9 pA, n = 7; p < 0.05, ANOVA), but not frequency (scrambled siRNA: 3.0 ± 0.6 Hz, n = 9; SAP97 siRNA: 2.7 ± 0.47 Hz, n = 7). Moreover, the enhancing effect of PD168077 on mEPSC was significantly diminished in neurons transfected with SAP97 siRNA (amplitude: 8 ± 3.0%, n = 7; frequency: 10.7 ± 4.1%, n = 7).

To examine the role of SAP97 further, we dialedyzed neurons with a peptide derived from the GluR1 C-terminal region containing the SSG sequence that is essential for the binding to SAP97 (37). As shown in Fig. 5D, loading the SSG peptide (50
to disrupt GluR1/SAP97 interaction prevented the PD168077-induced increase of AMPAR-EPSC in TTX-pretreated PFC pyramidal neurons (11.2 ± 3.9%, n = 7, Fig. 5F), whereas a scrambled control peptide was ineffective (54.9 ± 8.2%, n = 7, Fig. 5F). Dialysis of the SSG peptide alone did not induce significant changes in basal AMPAR-EPSC (data not shown).

Furthermore, we dialyzed neurons with an antibody against SAP97 (amino acids 1–229) to block the function of endogenous SAP97. As shown in Fig. 5E, the enhancing effect of PD168077 on AMPAR-EPSC was lost in PFC pyramidal neurons (TTX-pretreated) injected with anti-SAP97 (10 μg/ml) versus a scrambled control peptide (Δ), or anti-SAP97 (10 μg/ml) versus the heat-inactivated antibody (■). In contrast, dialysis with anti-SAP97 did not alter the reducing effect of PD168077 on AMPAR-EPSC in bicuculline-pretreated PFC pyramidal neurons (44.4 ± 3.5%, n = 7; supplemental Fig. 1E). These lines of evidence suggest that D₄-induced potentiation of AMPAR transmission in PFC pyramidal neurons at the low activity state is through a mechanism involving CaMKII/SAP97-mediated delivery of AMPARs to the synaptic membrane.

DISCUSSION

Our recent studies have revealed the D₄-induced, CaMKII-dependent homeostatic regulation of AMPAR trafficking and function in PFC pyramidal neurons (21). In this study, we have revealed the mechanism downstream of CaMKII that underlies the unique action of D₄ on AMPA receptors in PFC pyramidal neurons (Fig. 6). At the high activity state, D₄ receptors depress AMPAR-EPSC via a mechanism involving decreased CaMKII activity and reduced transport of AMPAR subunits along dendritic microtubules. At the low activity state, D₄ receptors potentiate AMPAR-EPSC via a mechanism depending on increased CaMKII activity and enhanced synaptic delivery of AMPA receptors via SAP97.

It is known that AMPAR trafficking plays a key role in controlling synaptic strength and plasticity. After being synthesized in the cell body, AMPARs are inserted into intracellular vesicles and move to dendrites where they become incorporated into synapses. Several mechanisms have been proposed to be important for regulating the localization of AMPARs at the synaptic membrane, including PDZ domain-mediated interac-
Mechanisms for D₄ Modulation of AMPARs

On the other hand, the D₄ potentiation of AMPAR-EPSC at the low activity state involves the D₄ increase of CaMKII activity via the phospholipid pathway (23) and the CaMKII-induced synaptic delivery of AMPARs (21). How does activated CaMKII recruit AMPARs to synapses? Detailed mechanisms remain elusive. There is evidence showing that it requires the GluR1 and PDZ domain interaction (39). The GluR1 C terminus specifically binds to the PDZ-domain-containing protein SAP97 (36, 37). Overexpression of SAP97 leads to an increase in synaptic AMPA receptors, spine enlargement, and an increase in mEPSC frequency (45). Moreover, overexpression of SAP97 during development traffics AMPARs to synapses (46), suggesting that SAP97 is part of the machinery that controls AMPAR trafficking. Genetic deletion of SAP97 does not alter synaptic transmission, which may be due to the compensation of other PSD-membrane-associated guanylate kinases (46). Consistently, we have found that knockdown of SAP97 with siRNA or disruption of GluR1/SAP97 interaction with the SSG peptide has little effect on basal mEPSC amplitude or frequency. However, the D₄/CaMKII-induced enhancement of mEPSC in TTX-pretreated neurons is blocked by SAP97 siRNA or SSG peptide, suggesting that SAP97 is involved in D₄/CaMKII-dependent delivery of AMPARs to synapses. At the low activity state, D₄ stimulation increases CaMKII activity, which could trigger SAP97 phosphorylation at Ser³⁹, causing increased targeting of SAP97 into dendritic spines (38). Consequently, GluR1, which binds to SAP97 (36, 37), is recruited to synapses. It awaits to be investigated how SAP97 is synaptic redistributed upon CaMKII phosphorylation.

Despite the variety of in vitro data indicating that AMPAR interactions with PDZ domain-containing proteins may be an important step for regulating the level of synaptic AMPARs during bi-directional plasticity, mice lacking the C-terminal PDZ ligand of GluR1 show no change in AMPAR trafficking, basal synaptic transmission, long-term potentiation or long-term depression (47). This suggests that the properties of AMPAR trafficking in cultures may be different from those in vivo. Whether SAP97 is required for the D₄-induced increase of synaptic GluR1 subunits in low activity cortical neurons in vivo awaits further investigation.

It is well recognized that dopaminergic inputs to the PFC are important for PFC-mediated cognitive functions including working memory (3–5). Because PFC excitatory transmission plays a key role in these cognitive processes (48), glutamate synapse components are the potential major targets of dopamine in PFC networks. PFC pyramidal cell excitability is enhanced or attenuated by the D₁ or D₂ receptor, respectively, via distinct mechanisms, depending on the glutamate receptor subtypes involved (49). Dopamine has been found to increase AMPAR amplitude in layer II–III PFC pyramidal neurons via a D₁-mediated postsynaptic signaling cascade involving Ca²⁺, PKA, and CaMKII (50). The dopamine-mediated reduction of excitatory neurotransmission in PFC pyramidal neurons has also been reported (51, 52). In PFC cultures, D₁ facilitates AMPAR synaptic insertion via a PKA-dependent mechanism, whereas D₂ decreases surface and synaptic GluR1 expression (53). Moreover, in ventral tegmental area-PFC co-cultures, dopamine agonists act on D₁ receptors on PFC neurons, alter-
ing their excitatory transmission onto ventral tegmental area dopamine neurons, thus influencing AMPARs (54). In contrast to the positive or negative impact of D₄ or D₂ receptors on AMPAR trafficking and glutamatergic transmission in PFC neurons, our studies (21 and the present one) have shown that D₄ receptors exert a dynamic effect. At the high activity state, D₄ receptor, via CaMKII inhibition, reduces both GluR1 and GluR2 from synaptic membrane; at the low activity state, D₄ receptors exert a dynamic effect. At the high activity state, D₄ to synaptic membrane (21). This homeostatic regulation supports and Jia Chen for help in some of the experiments.

**Acknowledgments**—We thank Xiaoming Chen for excellent technical support and Jia Chen for help in some of the experiments.

**REFERENCES**
1. Wise, R. A. (2004) *Nat. Rev. Neurosci.* 5, 483–494
2. Kehagia, A. A., Murray, G. K., and Robbins, T. W. (2010) *Curr. Opin. Neurobiol.* 20, 199–204
3. Williams, G. V., and Goldman-Rakic, P. S. (1995) *Nature* 376, 572–575
4. Sawaguchi, T., and Goldman-Rakic, P. S. (1991) *Science* 251, 947–950
5. Wang, M., Vijayaraghavan, S., and Goldman-Rakic, P. S. (2004) *Science* 303, 853–856
6. Mrzljak, L., Bergson, C., Papp, M., Huff, R., Levenson, R., and Goldman-Rakic, P. S. (1996) *Nature* 381, 245–248
7. Wedzony, K., Chocyk, A., Maetekowiak, M., Fijał, K., and Czyrak, A. (2000) *J. Physiol. Pharmacol.* 853–856
8. Van Tol, H. H., Bunzow, J. R., Guan, H. C., Sunahara, R. K., Seeman, P., and Goldman-Rakic, P. S. (1984) *Proc. Natl. Acad. Sci. U.S.A.* 813–822
9. Williams, G. V., and Goldman-Rakic, P. S. (1995) *Science* 273, 133–168
10. Schulman, H. (1984) *J. Cell Biol.* 99, 11–19

20. Zhang, K., Grady, C. J., Tsapakis, E. M., Andersen, S. L., Tanazzi, F. L., and Baldessarini, R. J. (2004) *Neuropsychopharmacology* 29, 1648–1655
21. Yuen, E. Y., Zhong, P., and Yan, Z. (2010) *Proc. Natl. Acad. Sci. U.S.A.* 107, 22308–22313
22. Gu, Z., Jiang, Q., Yuen, E. Y., and Yan, Z. (2006) *Mol. Pharmacol.* 69, 813–822
23. Gu, Z., and Yan, Z. (2004) *Mol. Pharmacol.* 66, 948–955
24. Yuen, E. Y., Liu, W., Kafri, T., van Praagh, H., and Yan, Z. (2010) *J. Physiol.* 588, 2361–2371
25. Yuen, E. Y., Jiang, Q., Feng, J., and Yan, Z. (2005) *J. Biol. Chem.* 280, 29420–29427
26. Yuen, E. Y., Liu, W., Karatsoreos, I. N., Feng, J., McEwen, B. S., and Yan, Z. (2009) *Proc. Natl. Acad. Sci. U.S.A.* 106, 14075–14079
27. Caceres, A., Mautino, J., and Kosik, K. S. (1992) *Neuron* 9, 607–618
28. Setou, M., Seog, D. H., Tanaka, Y., Kanai, Y., Takei, Y., Kawagishi, M., and Hirokawa, N. (2002) *Nature* 417, 83–87
29. Daw, M. I., Chittajallu, R., Bortolotto, Z. A., Dev, K. K., Duprat, F., Henley, J. M., Collingridge, G. L., and Isaac, J. T. (2000) *Neuron* 28, 873–886
30. Banani, E., Murray, J. W., Stockert, R. J., Satir, P., and Wolkoff, A. W. (2000) *J. Cell Biol.* 151, 179–186
31. Kim, C. H., and Lisman, J. E. (2001) *J. Neurosci.* 21, 4188–4194
32. Caceres, A., Binder, L. I., Payne, M. R., Bender, P., Rehuhn, L., and Steward, O. (1994) *J. Neurosci.* 4, 394–410
33. Sánchez, C., Díaz-Nido, J., and Avila, J. (2000) *Prog. Neurobiol.* 61, 133–168
34. Gao, C., and Wolf, M. E. (2007) *J. Neurosci.* 27, 19518–19524
35. Cai, C., Coleman, S. K., Niemi, K., and Keinanen, K. (2002) *J. Biol. Chem.* 277, 31484–31490
36. Mauceri, D., Cattabeni, F., Di Luca, M., and Gardoni, F. (2004) *J. Biol. Chem.* 279, 23813–23821
37. Hayashi, Y., Shi, S. H., Esteban, J. A., Piccini, A., Poncer, J. C., and Malinow, R. (2000) *Science* 287, 2262–2267
38. Eliás, G. M., Funke, L., Stein, V., Grant, S. G., Bredt, D. S., and Malinow, R. (2002) *Science* 298, 669–662
39. Zhou, Q., Xiao, M., and Nicol, R. A. (2001) *Proc. Natl. Acad. Sci. U.S.A.* 98, 1261–1266
40. Rumbaugh, G., Sia, G. M., Garner, C. C., and Huganir, R. L. (2003) *J. Neurosci.* 23, 4567–4576
41. Correia, S. S., Bassani, S., Brown, T. C., Lisé, M. F., Backos, D. S., Elsässer, R., Sia, G. M., and Wang, Y. T. (2000) *Neuron* 25, 649–662
42. Carroll, R. C., Beattie, E. C., Xia, H., Lüscher, C., Altschuler, Y., Nicoll, R. A., and Malenka, R. C., and von Zastrow, M. (1999) *Proc. Natl. Acad. Sci. U.S.A.* 96, 14112–14117
43. Tan, H. Y., Lin, J. W., Ju, W. H., Ahmadian, G., Liu, L., Becker, E. L., Sheng, M., and Wang, Y. T. (2000) *Neuron* 25, 649–662
44. Zhou, Q., Xiao, M., and Nicol, R. A. (2001) *Proc. Natl. Acad. Sci. U.S.A.* 98, 1261–1266
45. Correia, S. S., Bassani, S., Brown, T. C., Lisé, M. F., Backos, D. S., El-Husseini, A., Passafaro, M., and Esteban, J. A. (2008) *Nat. Neurosci.* 11, 457–466
46. Man, H. Y., Lin, J. W., Ju, W. H., Ahmadian, G., Liu, L., Becker, E. L., Sheng, M., and Wang, Y. T. (2000) *Neuron* 25, 649–662
47. Zhou, Q., Xiao, M., and Nicol, R. A. (2001) *Proc. Natl. Acad. Sci. U.S.A.* 98, 1261–1266
48. Correia, S. S., Bassani, S., Brown, T. C., Lisé, M. F., Backos, D. S., El-Husseini, A., Passafaro, M., and Esteban, J. A. (2008) *Nat. Neurosci.* 11, 457–466
49. Rumbaugh, G., Sia, G. M., Garner, C. C., and Huganir, R. L. (2003) *J. Neurosci.* 23, 4567–4576
50. Howard, M. A., Elias, G. M., Elias, L. A., Swat, W., and Nicol, R. A. (2010) *Proc. Natl. Acad. Sci. U.S.A.* 107, 3805–3810
51. Kim, C. H., Takamiya, K., Petralia, R. S., Sattler, R., Yu, S., Zhou, W., Kalb, R., Wenthold, R., and Huganir, R. (2005) *Nat. Neurosci.* 8, 985–987
52. Goldman-Rakic, P. S. (1995) *Neuron* 14, 477–485
53. Tseng, K. Y., and O'Donnell, P. (2004) *J. Neurosci.* 24, 5131–5139
54. Gonzalez-Islas, C., and Hablitz, J. J. (2003) *J. Neurosci.* 23, 867–875
55. Gao, W. J., Krimer, L. S., and Goldman-Rakic, P. S. (2001) *Proc. Natl. Acad. Sci. U.S.A.* 98, 295–300
56. Otani, S., Blond, O., Desce, J. M., and Crépel, F. (1998) *Neuroscience* 85, 669–676